Medical Journals

Improvement of Diabetes, Obesity and Hypertension in Type 2 Diabetic Kkay Mice by Bis(Allixinato)oxovanadium(Iv) Complex.

Authors:
  • Adachi Yusuke
  • Yoshikawa Yutaka
  • Yoshida Jiro
  • Kodera Yukihiro
  • Katoh Akira
  • Takada Jitsuya
  • Sakurai Hiromu

From: Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan.

Biochemical and biophysical research communications

  • Publish Date: Jul 2006
  • ISSN: 0006-291X
  • Volume: 345
  • Issue: 3
  • Pages: 945-50
  • Medium: Print
  • Language: English
  • Citation (JAMA): Adachi Yusuke, Yoshikawa Yutaka, Yoshida Jiro, et al. Improvement of Diabetes, Obesity and Hypertension in Type 2 Diabetic Kkay Mice by Bis(Allixinato)oxovanadium(Iv) Complex.. Biochem. Biophys. Res. Commun. Jul 2006;345:945-50

Abstract

Previously, we found that bis(allixinato)oxovanadium(IV) (VO(alx)(2)) exhibits a potent hypoglycemic activity in type 1-like diabetic mice. Since the enhancement of insulin sensitivity is involved in one of the mechanisms by which vanadium exerts its anti-diabetic effects, VO(alx)(2) was further tested in type 2 diabetes with low insulin sensitivity. The effect of oral administration of VO(alx)(2) was examined in obesity-linked type 2 diabetic KKA(y) mice. Treatment of VO(alx)(2) for 4 weeks normalized hyperglycemia, glucose intolerance, hyperinsulinemia, hypercholesterolemia and hypertension in KKA(y) mice; however, it had no effect on hypoadiponectinemia. VO(alx)(2) also improved hyperleptinemia, following attenuation of obesity in KKA(y) mice. This is the first example in which a vanadium compound improved leptin resistance in type 2 diabetes by oral administration. On the basis of these results, VO(alx)(2) is proposed to enhance not only insulin sensitivity but also leptin sensitivity, which in turn improves diabetes, obesity and hypertension in an obesity-linked type 2 diabetic animal.

Mesh Headings (Keywords): Animals, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Hypertension, Insulin Resistance, Leptin, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Models, Chemical, Obesity, Organometallic Compounds, Tissue Distribution


Check for Full Text / PubMed Unique Identifier (PMID): 16707105


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.